Uncategorized
ABIONYX Pharma Initiates Discussions With IRIS Pharma, a World Leader in Preclinical and Clinical Ophthalmology Research, With a View to a Possible Strategic Deal
TOULOUSE, France & LAKELAND, Mich.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma (Paris:ABNX) (FR0012616852 - ABNX - PEA PME eligible), a next-generation biotech company dedicated to the discovery and development of innovative therapies, announced today that it is initiating discussions with IRIS Pharma, a world leader in preclinical and clinical ophthalmology contract research, with a view to a possible strategic deal, in which IRIS Pharma's contract research business would remain separate